{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:36:13Z","timestamp":1760297773241},"reference-count":23,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Studies on cellular drug interactions with antiretroviral agents prior to clinical trials are critical to detect possible drug interactions. Herein, we demonstrated that two 2\u2032-deoxycytidine antiretroviral agents, dexelvucitabine (known as \u03b2-<jats:sc>d<\/jats:sc>-2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxy-5-fluorocytidine, DFC,<jats:sc>d<\/jats:sc>-d4FC, or RVT) and lamivudine (3TC), combined in primary human peripheral blood mononuclear (PBM) cells infected with human immunodeficiency virus 1 strain LAI (HIV-1<jats:sub>LAI<\/jats:sub>), resulted in additive-to-synergistic effects. The cellular metabolism of DFC and 3TC was studied in human T-cell lymphoma (CEM) and in primary human PBM cells to determine whether this combination caused any reduction in active nucleoside triphosphate (NTP) levels, which could decrease with their antiviral potency. Competition studies were conducted by coincubation of either radiolabeled DFC with different concentrations of 3TC or radiolabeled 3TC with different concentrations of DFC. Coincubation of radiolabeled 3TC with DFC at concentrations up to 33.3 \u03bcM did not cause any marked reduction in 3TC-triphosphate (TP) or any 3TC metabolites. However, a reduction in the level of DFC metabolites was noted at high concentrations of 3TC with radiolabeled DFC. DFC-TP levels in CEM and primary human PBM cells decreased by 88% and 94%, respectively, when high concentrations of 3TC (33.3 and 100 \u03bcM) were added, which may influence the effectiveness of DFC-5\u2032-TP on the HIV-1 polymerase. The NTP levels remained well above the median (50%) inhibitory concentration for HIV-1 reverse transcriptase. These results suggest that both \u03b2-<jats:sc>d<\/jats:sc>- and \u03b2-<jats:sc>l<\/jats:sc>-2\u2032-deoxycytidine analogs, DFC and 3TC, respectively, substrates of 2\u2032-deoxycytidine kinase, could be used in a combined therapeutic modality. However, it may be necessary to decrease the dose of 3TC for this combination to prove effective.<\/jats:p>","DOI":"10.1128\/aac.01543-06","type":"journal-article","created":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T00:54:34Z","timestamp":1175561674000},"page":"2130-2135","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Antiviral and Cellular Metabolism Interactions between Dexelvucitabine and Lamivudine"],"prefix":"10.1128","volume":"51","author":[{"given":"Brenda I.","family":"Hernandez-Santiago","sequence":"first","affiliation":[{"name":"Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory School of Medicine\/Veterans Affairs Medical Center, Decatur, Georgia 30033"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy S.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory School of Medicine\/Veterans Affairs Medical Center, Decatur, Georgia 30033"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim L.","family":"Rapp","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory School of Medicine\/Veterans Affairs Medical Center, Decatur, Georgia 30033"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"Grier","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory School of Medicine\/Veterans Affairs Medical Center, Decatur, Georgia 30033"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory School of Medicine\/Veterans Affairs Medical Center, Decatur, Georgia 30033"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.2646"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612053764869"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(94)90089-2"},{"key":"e_1_3_2_5_2","unstructured":"Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754 2004"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020501600502"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.10"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(84)90007-4"},{"key":"e_1_3_2_9_2","unstructured":"Antiretroviral activity and tolerability of reverset (D-d4FC) a new fluorocytidine nucleoside analog when used in combination therapy in treatment-experienced patients: results of phase IIb study RVT-203 2005"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020301400104"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.5.663"},{"key":"e_1_3_2_12_2","first-page":"159","year":"2004","unstructured":"Franklin, D., A. S. Roemer, and L. Placidi. 2004. The global antiviral therapeutics market, p. 159-184. In R. F. Schinazi and D. C. Liotta (ed.), Frontiers in nucleosides and nucleic acids. IHL Press, Tucker, GA.","journal-title":"Frontiers in nucleosides and nucleic acids"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.625-631.2006"},{"key":"e_1_3_2_14_2","first-page":"738","volume":"21","year":"1993","unstructured":"Hao, Z., E. E. Stowe, G. Ahluwalia, D. C. Baker, A. K. Hebbler, C. Chisena, S. M. Musser, J. A. Kelley, C.-F. Perno, D. G. Johns, and D. A. Cooney. 1993. Characterization of 2\u2032,3\u2032-dideoxycytidine diphosphocholine and 2\u2032,3\u2032-dideoxycytidine diphosphoethanolamine. Drug Metab. Dispos.21:738-744.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/315683"},{"key":"e_1_3_2_16_2","unstructured":"Lack of antagonistic interactions for the two cytidine analogs Reverset and lamivudine in vitro 2004"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109025200"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(96)00653-3"},{"key":"e_1_3_2_19_2","first-page":"110","year":"1991","unstructured":"Schinazi, R. F. 1991. Combined therapeutic modalities for viral infections\u2014rationale and clinical potential, p. 110-181. In T. C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, Orlando, FL.","journal-title":"Synergism and antagonism in chemotherapy"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1394-1401.2002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(93)90058-5"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.3854-3860.2002"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350400900410","volume":"9","year":"2004","unstructured":"Stuyver, L. J., T. R. McBrayer, D. Schurmann, I. Kravec, A. Beard, L. Cartee, R. F. Schinazi, A. de la Rosa, R. L. Murphy, and M. J. Otto. 2004. Potent antiviral effect of Reverset in HIV-1-infected adults following a single oral dose. Antivir. Ther.9:529-536.","journal-title":"Antivir. Ther."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1805"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01543-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01543-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T08:15:32Z","timestamp":1683792932000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01543-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1128\/AAC.01543-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.01543-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"2006-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-03-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}